ASXL1 and myelofibrosis: Of note, apart from the identification of TP53/ASXL1 and ASXL1 alone in one patient each, no high molecular risk mutations according to recently established clinico-genetic scoring systems for myelofibrosis, e.g. MIPSS70+, were identified in the remaining 8 patients.